General anesthesia using propofol infusion for implantation of an implantable cardioverter defibrillator in a pediatric patient with Andersen-Tawil syndrome: a case report

  • Seyeon Park (Department of Anesthesia and Pain Medicine, Pusan National University Yangsan Hospital) ;
  • Wonjae Heo (Department of Anesthesia and Pain Medicine, Pusan National University Yangsan Hospital) ;
  • Sang-Wook Shin (Department of Anesthesia and Pain Medicine, Pusan National University Yangsan Hospital) ;
  • Hye-Jin Kim (Department of Anesthesia and Pain Medicine, Pusan National University Yangsan Hospital) ;
  • Yeong Min Yoo (Department of Anesthesia and Pain Medicine, Pusan National University Yangsan Hospital) ;
  • Hee Young Kim (Department of Anesthesia and Pain Medicine, Pusan National University Yangsan Hospital)
  • Received : 2022.10.18
  • Accepted : 2022.12.11
  • Published : 2023.02.01


Andersen-Tawil syndrome (ATS) is a rare genetic disease characterized by a triad of episodic flaccid muscle weakness, ventricular arrhythmias, and physical anomalies. ATS patients have various cardiac arrhythmias that can cause sudden death. Implantation of an implantable cardioverter-defibrillator (ICD) is required when life-threatening cardiac arrhythmias do not respond to medical treatment. An 11-year-old girl underwent surgery for an ICD implantation. For general anesthesia in ATS patients, anesthesiologists should focus on the potentially difficult airway, serious cardiac arrhythmias, such as ventricular tachycardia (VT), and delayed recovery from neuromuscular blockade. We followed the difficult airway algorithm, avoided drugs that can precipitate QT prolongation and fatal cardiac arrhythmias, and tried to maintain normoxia, normocarbia, normothermia, normoglycemia, and pain control for prevention of sympathetic stimulation. We report the successful application of general anesthesia for ICD implantation in a pediatric patient with ATS and recurrent VT.



This work was supported by a 2022 research grant from the Pusan National University Yangsan Hospital.


  1. Nguyen HL, Pieper GH, Wilders R. Andersen-Tawil syndrome: clinical and molecular aspects. Int J Cardiol 2013; 170: 1-16.
  2. Yoon G, Oberoi S, Tristani-Firouzi M, Etheridge SP, Quitania L, Kramer JH, et al. Andersen-Tawil syndrome: prospective cohort analysis and expansion of the phenotype. Am J Med Genet A 2006; 140: 312-21.
  3. Apfelbaum JL, Hagberg CA, Connis RT, Abdelmalak BB, Agarkar M, Dutton RP, et al. 2022 American society of anesthesiologists practice guidelines for management of the difficult airway. Anesthesiology 2022; 136: 31-81.
  4. Airey KJ, Etheridge SP, Tawil R, Tristani-Firouzi M. Resuscitated sudden cardiac death in Andersen-Tawil syndrome. Heart Rhythm 2009; 6: 1814-7.
  5. Kleinsasser A, Loeckinger A, Lindner KH, Keller C, Boehler M, Puehringer F. Reversing sevoflurane-associated Q-Tc prolongation by changing to propofol. Anaesthesia 2001; 56: 248-50.
  6. Kweon TD, Nam SB, Chang CH, Kim MS, Lee JS, Shin CS, et al. The effect of bolus administration of remifentanil on QTc interval during induction of sevoflurane anaesthesia. Anaesthesia 2008; 63: 347-51.
  7. Schulze-Bahr E. Long QT syndromes: genetic basis. Card Electrophysiol Clin 2012; 4: 1-16.
  8. Perez-Riera AR, Barbosa-Barros R, Samesina N, Pastore CA, Scanavacca M, Daminello-Raimundo R, et al. Andersen-Tawil Syndrome: a comprehensive review. Cardiol Rev 2021; 29: 165-77.
  9. Dhamoon AS, Jalife J. The inward rectifier current (IK1) controls cardiac excitability and is involved in arrhythmogenesis. Heart Rhythm 2005; 2: 316-24.
  10. Airey K, Wilde A, Hofman N, Etheridge S, Ptacek L, Abuissa H, et al. Incidence of device therapy and complications in patients with andersen-tawil syndrome with ICDS. J Am Coll Cardiol 2011; 57: E1233. 
  11. Gold MR, Aasbo JD, El-Chami MF, Niebauer M, Herre J, Prutkin JM, et al. Subcutaneous implantable cardioverter-defibrillator post-approval study: clinical characteristics and perioperative results. Heart rhythm 2017; 14: 1456-63.
  12. Michaloudis DG, Kanakoudis FS, Xatzikraniotis A, Bischiniotis TS. The effects of midazolam followed by administration of either vecuronium or atracurium on the QT interval in humans. Eur J Anaesthesiol 1995; 12: 577-83. 
  13. O'Hare M, Maldonado Y, Munro J, Ackerman MJ, Ramakrishna H, Sorajja D. Perioperative management of patients with congenital or acquired disorders of the QT interval. Br J Anaesth 2018; 120: 629-44.
  14. Saarnivaara L, Simola M. Effects of four anticholinesterase-anticholinergic combinations and tracheal extubation on QTc interval of the ECG, heart rate and arterial pressure. Acta Anaesthesiol Scand 1998; 42: 460-3.
  15. Booker PD, Whyte SD, Ladusans EJ. Long QT syndrome and anaesthesia. Br J Anaesth 2003; 90: 349-66.
  16. Theodotou N, Cillo JE Jr. Brugada syndrome (sudden unexpected death syndrome): perioperative and anesthetic management in oral and maxillofacial surgery. J Oral Maxillofac Surg 2009; 67: 2021-5.
  17. Wynn RL. Articaine 4% with 1:200,000 epinephrine: an acceptable option for patients with long QT syndrome. Gen Dent 2007; 55: 176-8. 
  18. Oliveira ACG, Neves ILI, Sacilotto L, Olivetti NQS, Santos-Paul MAD, Montano TCP, et al. Is it safe for patients with cardiac channelopathies to undergo routine dental care? Experience from a single-center study. J Am Heart Assoc 2019; 8: e012361. 
  19. Venance SL, Cannon SC, Fialho D, Fontaine B, Hanna MG, Ptacek LJ, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain 2006; 129: 8-17.